Goldman Sachs
ACET icon

Goldman Sachs’s Adicet Bio ACET Stock Holding History

Goldman Sachs’s Portfolio ACET Stock Details ACET Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-234,510
Closed -$1.97M – 6433
2025
Q4 		$1.97M Buy
234,510
+34
+0% +$376 ﹤0.01% 4599
2025
Q3 		$3.04M Sell
234,476
-30
-0% -$353 ﹤0.01% 4101
2025
Q2 		$2.29M Sell
234,506
-4,029
-2% -$42.5K ﹤0.01% 4072
2025
Q1 		$2.88M Buy
238,535
+3,981
+2% +$56.9K ﹤0.01% 3861
2024
Q4 		$3.61M Sell
234,554
-446
-0.2% -$8.42K ﹤0.01% 3779
2024
Q3 		$5.41M Sell
235,000
-32,711
-12% -$732K ﹤0.01% 3272
2024
Q2 		$5.18M Buy
267,711
+17,362
+7% +$465K ﹤0.01% 3119
2024
Q1 		$9.41M Buy
250,349
+248,561
+13,902% +$10.3M ﹤0.01% 2510
2023
Q4 		$54.1K Sell
1,788
-1,931
-52% -$42.1K ﹤0.01% 5366
2023
Q3 		$81.5K Sell
3,719
-655
-15% -$23.1K ﹤0.01% 5219
2023
Q2 		$170K Sell
4,374
-1,833
-30% -$162K ﹤0.01% 5236
2023
Q1 		$572K Sell
6,207
-11,807
-66% -$1.48M ﹤0.01% 4752
2022
Q4 		$2.58M Sell
18,014
-6,679
-27% -$1.67M ﹤0.01% 3736
2022
Q3 		$5.62M Buy
24,693
+3,096
+14% +$786K ﹤0.01% 3031
2022
Q2 		$5.04M Buy
21,597
+7,345
+52% +$1.61M ﹤0.01% 3122
2022
Q1 		$4.55M Buy
14,252
+4,025
+39% +$926K ﹤0.01% 3444
2021
Q4 		$2.86M Buy
10,227
+7,851
+330% +$1.35M ﹤0.01% 3933
2021
Q3 		$298K Buy
2,376
+1,403
+144% +$174K ﹤0.01% 5504
2021
Q2 		$160K Sell
973
-1,887
-66% -$384K ﹤0.01% 5829
2021
Q1 		$598K Buy
2,860
+2,220
+347% +$510K ﹤0.01% 4984
2020
Q4 		$144K Buy
+640
New +$131K ﹤0.01% 5199
2020
Q3 		– Sell
-770
Closed -$185K – 5272
2020
Q2 		$185K Buy
770
+279
+57% +$54.8K ﹤0.01% 4815
2020
Q1 		$56K Buy
491
+255
+108% +$37.8K ﹤0.01% 5031
2019
Q4 		$39K Buy
236
+75
+47% +$38K ﹤0.01% 5134
2019
Q3 		$160K Buy
161
+39
+32% +$43.5K ﹤0.01% 4878
2019
Q2 		$139K Sell
122
-76
-38% -$68.9K ﹤0.01% 4876
2019
Q1 		$152K Buy
198
+92
+87% +$83.6K ﹤0.01% 4859
2018
Q4 		$102K Sell
106
-491
-82% -$647K ﹤0.01% 4990
2018
Q3 		$1.01M Buy
+597
New +$779K ﹤0.01% 4052
2018
Q2 		– Sell
-95
Closed -$102K – 5619
2018
Q1 		$102K Buy
+95
New +$174K ﹤0.01% 5279

Other funds holding ACET

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Goldman Sachs's ACET Position: Q1 2026 in Review

Goldman Sachs sold out of Adicet Bio (ACET) in Q1 2026, closing a stake of 234,510 shares — an estimated $1.97M sold.

Goldman Sachs first reported a position in ACET in Q1 2018 and held it in 30 quarters. The position peaked at $9.41M in Q1 2024. 49 funds tracked by Wall St. Rank hold ACET as of Q1 2026.

  • Goldman Sachs reported no remaining Adicet Bio position as of Q1 2026 after selling out during the quarter.
  • Goldman Sachs sold 234,510 Adicet Bio shares in Q1 2026, an estimated $1.97M.
  • Goldman Sachs first reported a position in Adicet Bio in Q1 2018 and held it in 30 quarters.
  • Goldman Sachs's Adicet Bio position peaked at $9.41M in Q1 2024.
  • 49 funds tracked by Wall St. Rank held Adicet Bio as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.